查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1978134

全球生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計生物標記市場將從 2025 年的 2,092.1 億美元成長到 2034 年的 6,570.7 億美元，2026 年至 2034 年的複合年成長率為 13.56%。

受精準醫療和疾病早期檢測需求不斷成長的推動，全球生物標記市場正經歷強勁成長。生物標記廣泛應用於診斷、藥物研發和臨床研究，用於評估疾病進展和治療效果。癌症和心血管疾病等慢性病盛行率的上升進一步推動了市場擴張。

基因組學、蛋白質組學和分子診斷技術的進步是關鍵的成長要素。製藥公司擴大在臨床試驗中使用生物標記物，以提高藥物的療效和安全性。此外，研發投入的增加以及生技公司與學術機構之間合作的加強，正在加速創新。

展望未來，人工智慧（AI）和巨量資料分析的融合預計將對市場產生積極影響。個人化醫療的進步將進一步提升對生物標記檢測的需求。開發中國家醫療基礎設施的擴建也將創造新的機會。隨著診斷技術的不斷發展，生物標記市場有望實現長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球生物標記市場：按類型分類

  • 市場分析、洞察與預測
  • 安全生物標記
  • 療效生物標記
  • 預測性生物標記
  • 替代生物標記
  • 藥物動力學生物標記物
  • 預後生物標記
  • 檢驗生物標記

第5章 全球生物標記市場：依產品分類

  • 市場分析、洞察與預測
  • 消耗品
  • 服務
  • 軟體

第6章 全球生物標記市場：依應用分類

  • 市場分析、洞察與預測
  • 診斷
  • 藥物發現與開發
  • 個人化醫療
  • 疾病風險評估
  • 其他

第7章 全球生物標記市場：依疾病分類

  • 市場分析、洞察與預測
  • 癌症
  • 心血管疾病
  • 神經系統疾病
  • 免疫疾病
  • 其他

第8章 全球生物標記市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Epigenomics AG
    • GE HealthCare Technologies Inc
    • Johnson & Johnson Services Inc
    • Thermo Fisher Scientific Inc
    • Bio-Rad Laboratories Inc
    • Siemens Healthineers AG
    • QIAGEN NV
    • Merck KGaA
    • PerkinElmer Inc
    • Agilent Technologies Inc
    • Eurofins Scientific SE
簡介目錄
Product Code: VMR112113891

The Biomarkers Market size is expected to reach USD 657.07 Billion in 2034 from USD 209.21 Billion (2025) growing at a CAGR of 13.56% during 2026-2034.

The Global Biomarkers Market is experiencing strong growth due to rising demand for precision medicine and early disease detection. Biomarkers are widely used in diagnostics, drug development, and clinical research to assess disease progression and treatment response. Increasing prevalence of chronic diseases such as cancer and cardiovascular disorders is fueling market expansion.

Key growth drivers include advancements in genomics, proteomics, and molecular diagnostics technologies. Pharmaceutical companies are increasingly utilizing biomarkers in clinical trials to improve drug efficacy and safety. Additionally, growing investments in research and development and collaborations between biotech firms and academic institutions are accelerating innovation.

Looking ahead, the market is expected to benefit from integration with artificial intelligence and big data analytics. Personalized medicine initiatives will further increase demand for biomarker-based testing. Expanding healthcare infrastructure in developing economies will create new opportunities. As diagnostic technologies continue to evolve, the biomarkers market is poised for long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamic Biomarkers
  • Prognostics Biomarkers
  • Validation Biomarkers

By Product

  • Consumable
  • Services
  • Software

By Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Others

By Disease

  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, Abbott Laboratories, Epigenomics AG, GE HealthCare Technologies Inc, Johnson Johnson Services Inc, Thermo Fisher Scientific Inc, BioRad Laboratories Inc, Siemens Healthineers AG, QIAGEN NV, Merck KGaA, PerkinElmer Inc, Agilent Technologies Inc, Eurofins Scientific SE
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Safety Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Efficacy Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Surrogate Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Pharmacodynamic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Prognostics Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Validation Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOMARKERS MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Consumable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Disease Risk Assessment Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOMARKERS MARKET: BY DISEASE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Disease
  • 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Immunological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Type
    • 8.2.2 By Product
    • 8.2.3 By Application
    • 8.2.4 By Disease
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Type
    • 8.3.2 By Product
    • 8.3.3 By Application
    • 8.3.4 By Disease
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Type
    • 8.4.2 By Product
    • 8.4.3 By Application
    • 8.4.4 By Disease
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Type
    • 8.5.2 By Product
    • 8.5.3 By Application
    • 8.5.4 By Disease
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Type
    • 8.6.2 By Product
    • 8.6.3 By Application
    • 8.6.4 By Disease
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOMARKERS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 F. Hoffmann-La Roche Ltd
    • 10.2.2 Abbott Laboratories
    • 10.2.3 Epigenomics AG
    • 10.2.4 GE HealthCare Technologies Inc
    • 10.2.5 Johnson & Johnson Services Inc
    • 10.2.6 Thermo Fisher Scientific Inc
    • 10.2.7 Bio-Rad Laboratories Inc
    • 10.2.8 Siemens Healthineers AG
    • 10.2.9 QIAGEN N.V
    • 10.2.10 Merck KGaA
    • 10.2.11 PerkinElmer Inc
    • 10.2.12 Agilent Technologies Inc
    • 10.2.13 Eurofins Scientific SE